Page 1209 - Basic _ Clinical Pharmacology ( PDFDrive )
P. 1209
Index 1195
structure of, 162, 163f Biological License Application (BLA), 17 Blood clotting factors, 610t,
toxicity of, 169–170 Biologics, for inflammation, 643 610–611, 611f
types of, 164t, 165–167 Biomagnification, 1006b Blood concentration-time curve, 47, 47f
variceal hemorrhage treated with, 1114 Biotransformation, drug, 56–73 Blood:gas partition coefficient, 443t, 444,
b-selective agonists, 141t, 149, 149f commensal gut microbiota in, 69–70 444f
b 1 -selective agonists, 99t, 141t, 149, 149f, in drug disposition, 57, 57f Blood glucose, self-monitoring of, 753
154t drug metabolism in Blood pressure
b 2 -selective agonists, 154t, 362t clinical relevance of, 64–72 angiotensin II on, 303
asthma treated with, 351 to toxic products, 64–65, 65f female hormonal contraceptives effect
preparations available, 363t in liver, 57–58 on, 733
structure of, 149f liver P450 enzymes in, 59–61, 62t–63t regulation of, 173–175
b 3 -selective agonists, 154t necessity for, 56–57 normal, 174f, 174–175
Betaxolol. See also b-receptor antagonist phase II reactions in, 57, 57f, 63, 64f, 64t postural baroreflex in, 175, 175f
drugs phase I reactions in renal response to decreased blood
description of, 164t, 166, 168, 170t description of, 57, 57f pressure in, 175
hypertension treated with, 183 microsomal mixed function oxidase Blood schizonticides, 917, 918f
Bethanechol, 109, 109f, 118, 122t system and, 58f, 58–59 B lymphocytes, 950
Bethanidine, 181 Biperiden, 501t, 508t Bond
Bevacizumab, 966t, 968, 991–992, 1065 Bipolar affective disorder covalent, 3–4
Bexarotene, dermatologic, 1085 drugs for, 524–528 drug–receptor, 3–4
Bezafibrate, 634 antipsychotics, 519 electrostatic, 3–4
Bezold-Jarisch reflex, 287 carbamazepine, 528, 529t hydrophobic, 3–4
Biased agonists, 141 lamotrigine, 528, 529t Bone marrow transplantation
at b receptors, 142b lithium, 524–528, 526, 529t immune globulin, intravenous for, 1180t
BIBP3226, 318t. See also Neuropeptide Y preparations available, 529t immunosuppressive therapy for, 996
antagonists valproic acid, 528, 529t Bone mineral homeostasis
Bicalutamide, 744, 972 history of, 524 calcitonin in, 773, 774f
Biguanides, 759–760, 768t nature of, 524 calcium and phosphate in, 772, 773f
BIIE0246, 318t. See also Neuropeptide Y pathophysiology of, 524 1,25-dihydroxyvitamin D in, 773, 774f
antagonists Bipyridines, 219, 225t Bone mineral homeostasis drugs, 772, 789t
Bile acid–binding resins, 636–637, 639t Bipyridyl herbicides, 1013f, 1014 clinical pharmacology of, 782–789
drug interactions of, 1161t Bisacodyl, 1099 calcium levels in, abnormal serum
with ezetimibe, niacin, and reductase Bismuth compounds, colloidal, 1100 hypercalcemia, 782–783
inhibitors, 639 Bismuth subcitrate potassium, 1096 hypocalcemia, 783–784
with fibric acid derivatives, 638 Bismuth subsalicylate, 1096 enteric oxaluria, 789
with HMG CoA reductase inhibitors, Bisoprolol. See also b-receptor antagonist mineral-regulating hormone uses in,
639 drugs 784–788
with niacin, 639 heart failure treated with, 221, 222, 225t chronic kidney disease, 785–786
Bile acid sequestrants hypertension treated with, 183 hereditary vitamin D–resistant
diabetes mellitus treated with, 764, 769t properties of, 164t rickets, 788
dyslipidemia treated with, 639t Bisphosphonates hyperparathyroidism, primary, 784
Bile acid therapy, for gallstones, bone homeostasis affected by, 779f, hypoparathyroidism, 784–785
1113–1114, 1116t, 1117t 779–781, 790t idiopathic hypercalciuria, 788
Bile salt–binding resins, 1100 bone metastases treated with, 789t intestinal osteodystrophy, 786
Bimatoprost hypercalcemia treated with, 782, 789t nephrotic syndrome, 788
glaucoma treated with, 337 osteoporosis treated with, 780b, 786, 789t nutritional rickets, 788
ophthalmic, 1085 Paget’s disease of bone treated with, 789 osteoporosis, 786–787, 787f
Binding sites, inert, 7 Bithionol, 939t, 940 pseudovitamin D deficiency rickets,
Binge drinking, 401 Bitopertin, 515 788
Bioaccumulation, 1006b Bivalirudin, 617–618 vitamin D deficiency/insufficiency,
Bioavailability, 47–48 Black cohosh, 1133t nutritional, 785
extent of absorption in, 47, 47f, 47t Blackwater fever, 924 X-linked and autosomal dominant
first-pass elimination in, 47–48 Black widow spider bite, 1180t hypophosphatemia, 787–788
rate of absorption in, 47f, 48 Bleach, household, 899 Paget’s disease of bone, 788–789
Biologic agents, for psoriasis, 1079 Bleomycin, 962t, 965–966 phosphate levels in, abnormal serum
fumaric acid esters, 1079 Blepharospasm, 106 hyperphosphatemia, 784
TNF inhibitors, 1079 Blind designs, 14 hypophosphatemia, 784
ustekinumab, 1079 Blood–brain barrier, 368–369 presentation in, 782